2016
DOI: 10.2139/ssrn.2875703
|View full text |Cite
|
Sign up to set email alerts
|

Observations of Biotech and Pharmaceutical Industry Merger and Acquisition Acquired In-Process Research and Development Impairment Indicators

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 9 publications
0
1
0
Order By: Relevance
“…as well as additional cost in the process [18][19][20]. In terms of the pharmaceutical industry, the studies for pharmaceutical companies mainly focused on R&D synergy of M&A with the biotechnology industry [21][22][23]. The integration of biotechnology with a similar R&D environment also presents various uncertainties regarding the improvement of pharmaceutical companies' performance [23].…”
Section: Introductionmentioning
confidence: 99%
“…as well as additional cost in the process [18][19][20]. In terms of the pharmaceutical industry, the studies for pharmaceutical companies mainly focused on R&D synergy of M&A with the biotechnology industry [21][22][23]. The integration of biotechnology with a similar R&D environment also presents various uncertainties regarding the improvement of pharmaceutical companies' performance [23].…”
Section: Introductionmentioning
confidence: 99%